01.13.23 -- Binge-worthy Episodes: In-Vivo Car T Update, The Future Of iPSCs, Abpro's Antibody Engine And More.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so you never miss an episode!

If you are responsible for manufacturing and outsourcing decisions at your company, check out our Cell & Gene Collaborative bi-weekly newsletter. Curated by director Anna Rose Welch, she singles out the most informative and entertaining manufacturing-centric headlines to keep you in the know.

Shoreline Biosciences CSO Robert Hollingsworth, Ph.D., joins Cell & Gene: The Podcast host Erin Harris for a discussion on intelligently designed allogeneic off-the-shelf, standardized, and targeted iPSC-derived natural killers and macrophage cellular immunotherapies.

BlueRock Therapeutics' CEO, Seth Ettenberg, Ph.D., talks to Cell & Gene: The Podcast listeners about the company's Phase 1 clinical trial for advanced Parkinson’s disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development and the major regulatory challenges the field faces for their clinical use.

Orgenesis’ CEO, Vered Caplan, explains the business model behind providing cell and gene therapies that may be manufactured at the point of care and the importance of enabling hospitals and providers to participate in CGT development on their sites and providing these therapies in-house by adapting them to closed system manufacturing rather than relying on the typical biotech model.

Recursion's unique, technology-aided approach to drug discovery has yielded one of the deepest, fastest-growing pipelines in emerging biotech. It starts with a 20-petabyte (and growing) database designed to create comprehensive "maps of biology" that enable insight into the relationships between molecules and cell types. On Business of Biotech, we take a deep dive into the approach with the company's CEO, Chris Gibson, Ph.D. Don't miss this window into the world of a true pioneer in computational biology.

Friend and frequent guest Allan Shaw rejoins Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in New York City. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. 

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that is considerably bigger. Osteoarthritis of the knee, or OA, is a chronic, progressive joint disease affecting over 30 million in the U.S. and over 300 million worldwide. Business of Biotech welcomes chief medical officer Dr. Howard Rutman to discuss their plasmid DNA gene therapy that's showing promise in OA and other chronic inflammatory conditions.

In an industry that takes business naming to extremes, Abpro is a refreshingly clear exception. Brothers Ian and Eugene Chan are antibody pros. Their pipeline spans no fewer than eight antibody candidates aimed at COVID-19, various cancers, DME, and wet AMD. With a scientific advisory board led by Bob Langer of Moderna fame and a new Celltrion partnership worth a potential $1.75 billion, they’re on the move.

This episode finds us getting the inside story from Umoja’s chief operating officer, David Fontana, Ph.D., whose storied career includes leadership positions at heavyweights including Sanofi, SeaGen, Pfizer, Juno, and BMS. Fontana shares on how he applies his experience playing a lead role in the success of Breyanzi, Adcetris, Bavencio, and Relatlimab in his new role at Umoja, the outsourcing battle scars that motivated the company to build its own 146,000 square foot development and manufacturing facility, and much more.